Physician profile
Eric A Meier
NPI 1720076656
$10,464.29
in general payments reported to CMS, 2019-2025
32 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,135 · 2020: $403 · 2021: $490 · 2022: $937 · 2023: $835 · 2024: $1,335 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Consulting Fee: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.41 |
| Consulting Fee | $171.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,536.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,091.28 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,028.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $758.21 | 2019-2025 | |
| Adma Biomanufacturing LLC | $391.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.49 | 2020-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $286.55 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $216.90 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $204.52 | 2021-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $199.27 | 2019-2025 | Dupixent |
| Csl Behring | $165.39 | 2021-2025 | Hizentra, Haegarda |
| Shire North American Group INC | $136.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.65 | 2019-2021 | |
| Pharming Healthcare, INC. | $119.45 | 2019-2025 | Ruconest |
| Horizon Therapeutics Plc | $108.84 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $101.89 | 2022-2025 | Orladeyo |
| Pfizer INC. | $84.59 | 2020-2025 | |
| Genentech, INC. | $81.10 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $71.07 | 2019-2025 | |
| Blueprint Medicines Corporation | $68.46 | 2024-2025 | Ayvakit |
| Leo Pharma INC. | $54.50 | 2022-2023 | Adbry |
| Ionis Pharmaceuticals, INC. | $52.94 | 2025 | Dawnzera |
| Alk-Abello, INC | $38.11 | 2021-2024 | Grastek, Ragwitek, Odactra |
| Kaleo, INC. | $31.03 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $21.09 | 2025 | Neffy |
| Optinose US, INC. | $20.52 | 2020 | |
| Galderma Laboratories, L.P. | $17.05 | 2025 | Nemluvio |
| Abbvie INC. | $16.84 | 2022 | |
| Lilly USA, LLC | $16.83 | 2025 | Ebglyss |
| Sunovion Pharmaceuticals INC. | $14.12 | 2020 | |
| Philips North America LLC | $12.86 | 2021 | |
| Organon LLC | $8.86 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.